Reliance Industries' subsidiary Karkinos Healthcare completes HPV DNA screening for over 100,000 women across India

Image for Reliance Industries' subsidiary Karkinos Healthcare completes HPV DNA screening for over 100,000 women across India

A woman in India dies of cervical cancer every 8 minutes.

Let that sit for a second.

It's the country's second-deadliest cancer for women.

Roughly 77,000 deaths a year.

India alone carries nearly one-third of the world's cervical cancer burden.

And the cruel part?

It's one of the most preventable cancers on the planet.


🧬 Enter a quiet 1,00,000-woman milestone

While everyone was busy debating Reliance's AGM, EBITDA targets and β‚Ή1 trillion FMCG dreams…

a small subsidiary tucked inside the empire crossed a line that actually matters.

Karkinos Healthcare β€” a wholly owned step-down arm of Reliance Industries β€” has now completed HPV DNA screening for over 1,00,000 women across India.

Not in metros. Not in fancy clinics.

In districts. In small towns. In the places the health system usually forgets.


🎯 Why HPV DNA testing is the game changer

The WHO calls it the most reliable primary screen for cervical cancer.

More accurate than the old Pap smear.

Less frequent. More definitive.

But here's the catch India has always struggled with:

πŸ‘‰ Testing is easy. Follow-up is where women fall through the cracks.

A positive result means nothing if she never makes it back for diagnosis and treatment.

That's the gap Karkinos is trying to close.


πŸ› οΈ The model, in plain English

Karkinos didn't just buy machines and call it a day. It built a stitched-together system:

  • πŸ₯ Public health programmes
  • 🀝 Public-private partnerships
  • πŸ’Ό CSR-funded outreach
  • πŸ‘©β€βš•οΈ Nurse-assisted and self-sampling kits
  • πŸ“ District-level screening drives
  • πŸ“² A digital backbone that tracks every woman from awareness β†’ screening β†’ triage β†’ follow-up

The whole point: no woman gets a positive result and disappears from the system.

As Padma Shri Dr. Neerja Bhatla put it β€” testing at scale isn't the win. Carrying every positive case through to treatment is.


πŸ“‰ Meanwhile, the stock tells a different story

Reliance shares are down ~16.5% YTD in 2026.

A heavy drag on the Nifty 50.

At the AGM this week, Mukesh Ambani promised to more than double consolidated EBITDA in 5 years β€” across New Energy, Reliance Intelligence, FMCG and a $125–150B export push by 2032.

Big numbers. Big ambitions. Brokerages stayed bullish.


⚑ The real headline

Markets will obsess over the EBITDA chart.

But somewhere in a small Indian district today, a woman walked into a screening camp, gave a sample, and got pulled into a system that will actually call her back.

That's the kind of scale India has been waiting decades for.

One lakh down.

Millions to go.

That's all for now!